Last updated: September 9, 2026
Afluria and Afluria Quadrivalent are seasonal influenza vaccines marketed in the United States by Seqirus, the vaccine business of CSL Limited. Their commercial performance depends more on annual supply contracts, strain selection, manufacturing capacity, government procurement, and product mix than on patent exclusivity. CSL does not separately report Afluria revenue, so the product’s financial trajectory must be assessed through Seqirus results and broader influenza-vaccine market indicators.
Afluria has limited conventional patent risk. The products are biologics licensed under a Biologics License Application rather than small-molecule drugs approved under an NDA. They do not have a meaningful Orange Book exclusivity position, and a conventional Paragraph IV generic challenge is not the primary competitive pathway. Competition comes from other licensed influenza vaccines, including Fluzone, Fluarix, Fluad, FluMist and newer cell-based or recombinant products.
What are Afluria and Afluria Quadrivalent?
Afluria is an inactivated influenza vaccine manufactured by Seqirus. Afluria Quadrivalent protects against four influenza strains and replaced the trivalent formulation as the principal U.S. product after quadrivalent vaccines became the market standard.
| Product |
Sponsor and manufacturer |
FDA regulatory pathway |
Dosage form |
Commercial role |
| Afluria |
Seqirus Inc., CSL Limited |
BLA 125254 |
Inactivated influenza vaccine |
Legacy trivalent product |
| Afluria Quadrivalent |
Seqirus Inc., CSL Limited |
Supplement to BLA 125254 |
Prefilled syringe and multidose vial |
Current principal Afluria formulation |
| Fluad and Fluad Quadrivalent |
Seqirus Inc. |
Separate biologic license |
Adjuvanted influenza vaccine |
Older-adult segment |
| Flucelvax Quadrivalent |
Seqirus Inc. |
Separate biologic license |
Cell-based influenza vaccine |
Cell-based segment |
Afluria Quadrivalent received FDA approval in 2016. Its label has been updated through annual strain changes and manufacturing supplements. The vaccine is administered intramuscularly, with presentations and age indications determined by the applicable seasonal label. FDA-approved seasonal influenza vaccines are reformulated each year to reflect public-health recommendations and circulating strains. [1]
What is the FDA regulatory status of Afluria Quadrivalent?
Afluria Quadrivalent is an FDA-licensed seasonal influenza biologic. Its regulatory status is tied to BLA 125254 and subsequent supplements rather than a conventional NDA.
The FDA’s annual influenza vaccine listings identify Afluria Quadrivalent among licensed vaccines available for the applicable season. The FDA and CDC determine product recommendations, strain composition, age eligibility and presentation requirements on a seasonal basis. [1, 2]
The regulatory model creates recurring manufacturing and compliance requirements:
- Annual strain updates.
- Potency and sterility testing for each lot.
- Validation of manufacturing changes.
- Supply-chain execution within a narrow pre-season window.
- Postmarketing surveillance for safety and effectiveness.
- Compliance with FDA lot-release and biologics-manufacturing requirements.
Afluria is not an over-the-counter pharmaceutical product. Its commercial availability depends on licensed distribution, pharmacy and provider channels, government purchasing and seasonal immunization demand.
When does Afluria lose exclusivity?
Afluria does not have a single commercially decisive patent-expiration date. Its market protection is based on regulatory licensure, manufacturing capability, supply agreements, brand recognition and seasonal execution.
The original Afluria approval dates from the 2000s, and the statutory 12-year reference-product exclusivity period for a newly licensed biologic has expired. Afluria Quadrivalent was approved in 2016, but that approval did not create a durable monopoly comparable to a patented specialty drug. Seasonal influenza vaccines are subject to direct competition from multiple independently licensed products.
| Exclusivity category |
Afluria position |
| New biologic reference-product exclusivity |
Expired for the legacy Afluria product |
| Orange Book listing |
Not applicable as the primary framework |
| Paragraph IV certification |
Not applicable to a BLA-only product |
| Pediatric exclusivity |
No commercially material exclusivity position identified |
| Patent-based market exclusivity |
No publicly disclosed core patent date controlling U.S. entry |
| Seasonal formulation protection |
Repeated regulatory and manufacturing approvals, not patent exclusivity |
| Interchangeable biosimilar protection |
No meaningful current role |
The practical answer is that Afluria loses exclusivity through competitive substitution rather than through a single patent cliff.
What patents protect Afluria and Afluria Quadrivalent?
No publicly disclosed patent appears to provide Afluria Quadrivalent with a blocking U.S. monopoly over the seasonal vaccine market. Influenza vaccine patents may cover manufacturing processes, cell culture, antigen production, purification, packaging, delivery devices or platform technologies, but those rights do not necessarily protect the marketed Afluria formulation.
The principal intellectual-property assets are likely to include:
- Manufacturing know-how for antigen production and purification.
- Process controls for viral growth, inactivation and quality testing.
- Strain selection and scale-up expertise.
- Facility-specific validation data.
- Trade secrets related to yield, stability and lot consistency.
- Contracting relationships and demand-planning systems.
These assets are commercially important but difficult to measure through public patent records. They also do not prevent competitors from obtaining their own influenza-vaccine licenses.
Does Afluria have Orange Book-listed patents?
Afluria is not primarily governed by Orange Book patent listing. The FDA Orange Book covers approved drug products, therapeutic equivalents and patent or exclusivity information associated mainly with NDA products. Afluria is licensed as a biologic under a BLA.
The absence of a meaningful Orange Book position reduces the relevance of:
- Paragraph IV certifications.
- Thirty-month stays.
- ANDA-based generic litigation.
- Automatic generic substitution.
- A conventional patent-expiration launch date.
Are there Paragraph IV challenges to Afluria?
No conventional Paragraph IV challenge is expected for Afluria because Paragraph IV certifications apply to patents listed for NDA products in the Orange Book. A competitor seeking to market a competing influenza vaccine would generally pursue its own FDA biologics license or another applicable regulatory route rather than file an ANDA against Afluria.
This distinction matters for investors and business-development teams. The absence of Paragraph IV activity does not mean the product is insulated from competition. It means the competitive process occurs through separate biologic approvals, procurement decisions and commercial contracting.
What generic, biosimilar and competitive entry risks exist for Afluria?
Afluria faces high competitive exposure but low conventional generic risk. The relevant competitors are licensed influenza vaccines rather than substitutable small-molecule generics.
| Competitor |
Manufacturer |
Differentiating position |
| Fluzone Quadrivalent |
Sanofi |
Large established influenza-vaccine franchise |
| Fluzone High-Dose and related products |
Sanofi |
Older-adult positioning |
| Fluarix Quadrivalent |
GSK |
Broad retail and provider distribution |
| Fluad Quadrivalent |
Seqirus |
Adjuvanted product for older adults |
| Flucelvax |
Seqirus |
Cell-based production |
| FluMist |
AstraZeneca |
Intranasal live attenuated vaccine |
| Flublok |
Sanofi |
Recombinant influenza-vaccine platform |
| Vaxigrip and other regional products |
Sanofi and other manufacturers |
International competition |
Afluria’s primary risks are:
- Lower vaccination rates.
- Reduced demand from mild influenza seasons.
- Retail and pharmacy formulary changes.
- Government procurement shifts.
- Product-specific safety or effectiveness concerns.
- Manufacturing delays.
- Preference for cell-based, recombinant or adjuvanted products.
- Price competition among quadrivalent vaccines.
- Higher uptake of enhanced vaccines for older adults.
The biosimilar pathway is not currently the main threat. Influenza vaccines are not marketed as complex therapeutic biologics with automatic interchangeability dynamics. Competitors typically obtain independent licenses for their own products, and substitution depends on payer, pharmacy, provider and institutional procurement policies.
How strong is the patent estate for Afluria?
Afluria’s patent estate is weak as a standalone barrier to entry. Its commercial protection is stronger in manufacturing and regulatory execution than in product claims.
| Protection factor |
Assessment |
Business effect |
| Core composition patents |
Low |
Seasonal strains change and competitors use independent formulations |
| Orange Book leverage |
None or immaterial |
No standard Paragraph IV enforcement mechanism |
| Manufacturing know-how |
Moderate to strong |
Supports yield, quality and scale |
| Regulatory experience |
Strong |
Helps manage annual strain changes and lot release |
| Production capacity |
Strong if available |
Supports government and institutional contracts |
| Brand and distribution |
Moderate |
Supports pharmacy and provider uptake |
| Switching barriers |
Low to moderate |
Buyers can use competing licensed vaccines |
| Litigation leverage |
Low |
Limited evidence of product-blocking patent rights |
The product’s strongest barrier is operational. Influenza vaccines must be manufactured, tested and distributed before the vaccination season. A company with validated facilities, regulatory history and global capacity has advantages that are difficult to reproduce quickly, even without strong patent protection.
What financial trajectory does Afluria have?
CSL reports financial results for Seqirus as a business segment and does not disclose separate revenue for Afluria or Afluria Quadrivalent. The financial trajectory of Afluria therefore cannot be isolated from Seqirus’ other products, including Fluad, Flucelvax and other influenza vaccines.
CSL’s annual reports identify Seqirus as a major growth contributor. Seqirus generated approximately $6.1 billion in revenue in fiscal 2024, according to CSL’s annual reporting. The figure includes the full Seqirus portfolio and should not be attributed to Afluria alone. [3]
Financial drivers
Afluria’s revenue is shaped by volume, price, product mix and seasonal timing:
- U.S. vaccination rates.
- Public-sector orders.
- Employer and institutional programs.
- Pharmacy channel demand.
- Relative use of quadrivalent, adjuvanted and cell-based products.
- Manufacturing costs.
- Inventory write-offs after the influenza season.
- Timing of shipments before peak vaccination months.
- Government and health-system procurement terms.
The product’s recurring annual demand gives Afluria a more predictable commercial cycle than many specialty medicines, but the cycle is highly seasonal. A poor match between vaccine strains and circulating viruses can affect demand and perceived value. Production errors or late delivery can shift orders to competitors because customers cannot wait until the next season.
Revenue exposure
Afluria is financially material as part of the influenza portfolio but is not separately quantifiable from public filings. The largest revenue exposure is likely in the United States, where Seqirus maintains extensive pharmacy, provider, institutional and public-sector distribution. International influenza-vaccine sales also contribute to Seqirus results, but product availability and brand use vary by jurisdiction.
Investors should avoid using total Seqirus revenue as a proxy for Afluria revenue. Seqirus includes differentiated products with different pricing and growth profiles, particularly adjuvanted and cell-based vaccines.
What patent litigation affects Afluria?
No material Afluria-specific patent litigation is identified in CSL’s public fiscal 2024 reporting. The absence of reported litigation is consistent with the product’s BLA-based regulatory position and limited Orange Book relevance. [3]
The more likely disputes for Afluria would involve:
- Manufacturing contracts.
- Product liability.
- Procurement agreements.
- Regulatory compliance.
- Trade secrets.
- Facility and supply arrangements.
- Vaccine injury claims.
These disputes would not create the same launch-delay mechanics as ANDA litigation involving a patented small-molecule drug.
What licensing deals and partnerships support Afluria?
Afluria is supported by Seqirus’ integration into CSL’s vaccine operations. CSL acquired the former bioCSL influenza vaccine business from Novartis in 2015, creating the current Seqirus structure. [4]
The important commercial relationships are expected to involve:
- Government procurement.
- Pharmacy chains.
- Wholesalers.
- Health systems.
- Employer vaccination programs.
- Public-health agencies.
- Contract manufacturing and distribution.
Public disclosures do not identify a product-specific Afluria licensing deal that materially changes ownership or exclusivity. The key strategic asset is CSL’s vertically integrated vaccine platform and global manufacturing network.
How does Afluria compare with competing influenza vaccines?
Afluria competes effectively on supply, distribution and brand recognition but lacks a unique patent-protected mechanism.
| Factor |
Afluria Quadrivalent |
Fluzone Quadrivalent |
Fluarix Quadrivalent |
Fluad Quadrivalent |
Flucelvax |
| Technology |
Egg-based inactivated |
Egg-based inactivated |
Egg-based inactivated |
Adjuvanted inactivated |
Cell-based |
| Principal advantage |
Established Seqirus supply |
Sanofi scale and brand |
GSK distribution |
Older-adult differentiation |
Cell-based platform |
| Patent-based barrier |
Limited |
Limited |
Limited |
Limited |
Platform and process IP |
| Main market risk |
Price and procurement |
Same |
Same |
Narrower target segment |
Higher production complexity |
| Generic substitution |
No |
No |
No |
No |
No |
Afluria’s closest direct competitors are Fluzone Quadrivalent and Fluarix Quadrivalent. Fluad and Flucelvax compete with Afluria through product segmentation rather than exact formulation equivalence.
What generic launch scenarios exist for Afluria?
A conventional generic launch scenario is unlikely. The realistic scenarios are:
- A competing manufacturer launches a separately licensed egg-based quadrivalent vaccine.
- A cell-based or recombinant vaccine gains share.
- Enhanced vaccines take volume from standard-dose products in older adults.
- Retail or government contracts shift to lower-priced suppliers.
- Seqirus migrates demand from Afluria into Fluad or Flucelvax.
- A supply disruption creates temporary share loss during a vaccination season.
A competitor does not need to invalidate an Afluria patent to enter the market. It needs an FDA license, sufficient manufacturing capacity and access to distribution or public procurement.
What is the geographic coverage of Afluria?
Afluria’s strongest commercial presence is in the United States. Seqirus also markets influenza vaccines internationally, although brand names, formulations, approvals and distribution arrangements differ by country.
Geographic risk varies by jurisdiction:
- United States: high competition, strong pharmacy channel, significant government purchasing.
- Europe: national procurement and country-specific regulatory requirements.
- Australia and other Southern Hemisphere markets: different seasonal timing and strain cycles.
- Emerging markets: greater sensitivity to affordability, public-health budgets and supply reliability.
Global manufacturing capacity is strategically important because Northern and Southern Hemisphere seasons require different production and distribution schedules.
Key Takeaways
- Afluria and Afluria Quadrivalent are Seqirus influenza vaccines within CSL’s broader vaccine portfolio.
- Afluria Quadrivalent is an FDA-licensed biologic under BLA 125254.
- The product does not have a meaningful Orange Book patent position.
- Paragraph IV litigation is not the relevant entry mechanism.
- Conventional biosimilar risk is limited; the main threat is competition from separately licensed vaccines.
- Afluria’s strongest protections are manufacturing know-how, regulatory execution, capacity and distribution.
- CSL does not report Afluria-specific revenue.
- Seqirus generated approximately $6.1 billion in fiscal 2024 revenue, but that figure includes products beyond Afluria.
- Financial performance depends on annual vaccination demand, product mix, government procurement, pricing and manufacturing reliability.
- The principal competitors are Sanofi’s Fluzone, GSK’s Fluarix, Seqirus’ own Fluad and Flucelvax, AstraZeneca’s FluMist and recombinant influenza vaccines.
FAQs About Afluria Patent Protection and Market Outlook
Is Afluria a biologic or a conventional pharmaceutical drug?
Afluria is a biologic influenza vaccine licensed under a BLA. It is not primarily regulated as an NDA-approved small-molecule drug.
Can a generic company file an ANDA for Afluria?
A conventional ANDA and Paragraph IV strategy is not the normal pathway. A competitor would generally seek its own biologics license for an influenza vaccine.
Does Afluria have a patent expiration date?
No single patent expiration date controls Afluria’s U.S. market. The product’s original regulatory exclusivity has expired, while seasonal competition continues through separate vaccine approvals.
Is Afluria interchangeable with Fluad or Flucelvax?
No. Fluad is an adjuvanted vaccine, and Flucelvax uses a cell-based manufacturing platform. Substitution depends on clinical recommendations, age, payer policy and procurement rules.
Does CSL disclose Afluria sales separately?
No. CSL reports Seqirus financial results at the business-segment level. Public filings do not provide separate Afluria or Afluria Quadrivalent revenue.
References
- U.S. Food and Drug Administration. (2024). Afluria Quadrivalent prescribing information and seasonal influenza vaccine approvals. FDA.
- Centers for Disease Control and Prevention. (2024). Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices. CDC.
- CSL Limited. (2024). Annual report 2024. CSL Limited.
- CSL Limited. (2015). CSL completes acquisition of Novartis influenza vaccine business. CSL Limited.
